Non-Hodgkin Lymphoma | Specialty

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Adding Brentuximab Vedotin to R-CHOP Induces 80% Response Rate in DLBCL

June 26th 2015

Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.

Novel Combination Strategies Explored in Two Phase III NHL Studies

June 26th 2015

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

Cheson on Obinutuzumab's Potential for Patients With Rituximab-Refractory iNHL

June 24th 2015

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

June 20th 2015

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

June 20th 2015

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

June 20th 2015

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Ibrutinib, Ublituximab, TGR-1202 Triplet Active in Relapsed B-Cell Malignancies

June 19th 2015

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

Obinutuzumab Doubles PFS in Refractory Indolent Non-Hodgkin Lymphoma

May 30th 2015

Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.

Radford Discusses Future of Novel Therapies in Non-Hodgkin Lymphoma

May 12th 2015

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

It's Time to Tackle the Evidence Gap in Lymphoid Cancers

May 6th 2015

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Vitamin D Deficient Follicular Lymphoma Patients Experience Higher Relapse Risk

April 22nd 2015

Low vitamin D levels prior to treatment may be linked to risk of relapse or death for patients with follicular lymphoma.

Novel Agents Set to Revolutionize NHL Treatment

April 13th 2015

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

Dr. Gascoyne on Predictive Biomarker Research in Lymphomas

April 8th 2015

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.

Predictive Biomarkers Key to Continued Progress in Non-Hodgkin Lymphoma

March 19th 2015

In an interview with OncLive, Randy Gascoyne, MD, explains how predictive biomarkers can help oncologists select the right therapies for their patients and why they are the critical next step to improving outcomes in NHL.

Dr. Randy Gascoyne on Biomarkers for Follicular Lymphoma

March 3rd 2015

Randy Gascoyne, MD, hematopathologist and research director for the Centre for Lymphoid Cancers at the BC Cancer Agency in Canada, discusses a study that investigated biomarkers for follicular lymphoma.